The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ELEVATION ONCOLOGY INC COM 28623U101   1,272,766 2,370,142 SH   SOLE   2,370,142 0 0
HILLEVAX INC COM 43157M102   8,970,714 558,923 SH   SOLE   558,923 0 0
ICOSAVAX INC COM 45114M109   55,321,193 3,510,228 SH   SOLE   3,510,228 0 0
JASPER THERAPEUTICS INC COM 471871103   6,722,002 8,519,648 SH   SOLE   8,519,648 0 0
KEZAR LIFE SCIENCES INC COM 49372L100   785,121 828,711 SH   SOLE   828,711 0 0
KORRO BIO INC COM 500946108   17,642,314 368,085 SH   SOLE   368,085 0 0
TOURMALINE BIO INC COM 89157D105   16,799,470 641,691 SH   SOLE   641,691 0 0
VENTYX BIOSCIENCES INC COM 92332V107   1,695,334 686,370 SH   SOLE   686,370 0 0